What's new? Log in Free sign up

MorphoSys (MPSYF)

Company Profile

Company profile

Ticker

MPSYF

Exchange

Website

www.morphosys.de/

CEO

Jean-Paul Kress

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology (except Nanobiotechnology)

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

MPSYF stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Automatic shelf registration (post-effective amendment)

Half-Year Report JANUARY – JUNE 2024

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

GOLDMAN SACHS GROUP INC

GOLDMAN SACHS GROUP INC

Kynam Capital Management, LP

Financial summary

Financial statements Chart MPSYF financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from MorphoSys earnings reports.

Institutional ownership, Q3 2024

MPSYF institutional ownership history Ownership history

94.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	33	-69.7%
Opened positions	2	7	-71.4%
Closed positions	25	36	-30.6%
Increased positions	3	8	-62.5%
Reduced positions	2	9	-77.8%

13F shares	Current	Prev Q	Change
Total value	2.53 bn	22.35 bn	-88.7%
Total shares	35.75 mm	35.53 mm	+0.6%
Total puts	0.00	673.00 k	EXIT
Total calls	0.00	79.80 k	EXIT
Total put/call ratio	–	8.4	–

Largest owners	Shares	Value	Change
NVS Novartis	35.61 mm	$0.00	+3.7%
Hennion & Walsh Asset Management	123.31 k	$2.34 bn	-1.0%
Rhumbline Advisers	5.19 k	$98.34 mm	0.0%
Simplex Trading	4.46 k	$0.00	NEW
GAMMA Investing	4.09 k	$77.58 mm	+42.4%
Parallel Advisors	1.49 k	$0.00	0.0%
Lindbrook Capital	1.25 k	$0.00	-0.6%
Thrivent Trust Co of Tennessee	966.00	$17.58 mm	+961.5%
Farther Finance Advisors	312.00	$0.00	0.0%
BCS Barclays	14.00	$1.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
NVS Novartis	35.61 mm	+1.27 mm	+3.7%
BLK BlackRock	0.00	-1.02 mm	EXIT
Engineers Gate Manager	0.00	-13.42 k	EXIT
Advisors Preferred	0.00	-6.50 k	EXIT
Quadrant Capital	0.00	-5.93 k	EXIT
Simplex Trading	4.46 k	+4.46 k	NEW
BAC Bank of America	0.00	-3.40 k	EXIT
UBS UBS	0.00	-3.32 k	EXIT
Signaturefd	0.00	-3.00 k	EXIT
C Citigroup	0.00	-2.09 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.